Quality of Life After Lower Respiratory Tract Infection

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Nottingham

About this trial

Lower respiratory tract infections (LRTIs) are any infections below the vocal cords which affect the airways or the air sacs in the lungs. They include pneumonia, bronchitis and chest infections and are usually caused by viruses such as influenza, COVID-19 or Respiratory Syncytial Virus (RSV), or by bacteria such as pneumococcus. LRTIs are common, particularly in older adults; in the UK approximately 15% of people aged over 65 years will experience a chest infection each year and many of those will need in-patient treatment.

People who have had a chest infection may experience slow recovery after their infection. Patients often report that their quality of life is worse after an infection (for example persistent fatigue, reduced physical functioning, and mental health challenges) and this can affect the return to usual activities. However, there have not been many studies that have looked at how the quality of life changes in the months following a chest infection, and why some people take longer to recover.

In this study, the investigators will use a well-recognised questionnaire to measure quality of life for up to one year in adults who have been admitted to hospital with a chest infection. The findings will help the investigators to assess how long-term quality of life is affected after a chest infection and what factors may affect it. The results will also permit calculation of the costs faced by patients during recovery from a chest infection, in financial terms. These results will feed into studies looking at ways of improving recovery after a chest infection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged ≥18years (no upper age limit).

Treated by attending physician as lower respiratory tract infection/community-acquired pneumonia, regardless of microbiologically-confirmed pathogen.

Ability to give informed consent or appropriate consultee available to give advice.

Disqualifiers

Hospital admission within 14 days preceding the index admission

Post-obstructive pneumonia secondary to Lung Cancer

Patients treated for active Tuberculosis (TB)

Receiving palliative treatment only

Trial population

Participants will be recruited from the adult respiratory wards at Nottingham City Hospital as the majority of patients with a primary diagnosis of lower respiratory tract infection are admitted to these wards.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

200 Participants
are grouped into 1 trial group
Group A: Lower respiratory tract infection

Trial outcomes

Primary outcomes

1

Change from baseline in health state utility values over one year

Health state utility values calculated from EQ-5D-5L profiles using preference-based value sets pre-discharge and at 1, 3, 6 and 12 months post-discharge.

Time frame
From enrolment to one year post-discharge from hospital

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: